In humans, a GRK5 sequence polymorphism at residue 41 (leucine rather than glutamine) that is most common in individuals with African ancestry leads to elevated GRK5-mediated desensitization of airway beta2-adrenergic receptors, a drug target in asthma.
A polymorphism in the GRK5 gene at residue 41, where leucine replaces glutamine, is prevalent among individuals of African descent and contributes to heightened desensitization of airway beta2-adrenergic receptors by GRK5, a target for asthma medications.